Journal rankings · indicator year 2013
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Field ranking · 2013
Pharmacology, Toxicology and Pharmaceutics journal rankings 2013
61 ranked journals · Field in Life Sciences
Pharmacology, Toxicology and Pharmaceutics has 61 ranked journals in 2013. The median OJR fell 0.15 on 2012 to 0.80, below the world average of 1.00; Q1 starts at OJR 1.42. The top three are Expert Opinion on Drug Delivery, Journal of Drug Delivery, and European Journal of Pharmaceutics and Biopharmaceutics.
Ranks and citation indicators: 2013. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2010–2012, the window the 2013 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields in Pharmacology, Toxicology and Pharmaceutics (4)
Up to Life Sciences61 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2012. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2010–2012, the window the 2013 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2010–2012 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2004 to 2013. | Compare |
|---|---|---|---|---|---|---|---|
1Expert Opinion on Drug DeliveryTaylor & Francis · United Kingdom | 2.23Q1 | 4.81 0.93 down from 2012 | 333 | 17% | — | ||
2Journal of Drug DeliveryHindawi Publishing Corporation · United Kingdom | 2.12Q1 | 4.46 0.48 up from 2012 | 81 | 100% | — | ||
3European Journal of Pharmaceutics and BiopharmaceuticsElsevier BV · Netherlands | 2.10Q1 | 4.08 0.15 down from 2012 | 694 | 16% | $4,210 | ||
4Pharmaceutical ResearchSpringer Science+Business Media · United States | 2.09Q1 | 4.28 0.96 down from 2012 | 884 | 30% | $4,690 | ||
5The Pharmacogenomics JournalSpringer Nature · United Kingdom | 2.04Q1 | 4.39 0.38 down from 2012 | 203 | 44% | $4,890 | ||
6Current Drug MetabolismBentham Science Publishers · Netherlands | 2.00Q1 | 3.49 1.44 down from 2012 | 314 | 6% | — | ||
7Critical Reviews in Therapeutic Drug Carrier SystemsBegell House · United States | 1.82Q1 | 4.83 1.05 up from 2012 | 34 | 5% | — | ||
8Drug Metabolism and DispositionAmerican Society for Pharmacology and Experimental Therapeutics · United States | 1.82Q1 | 3.98 0.15 up from 2012 | 861 | 39% | $3,500 | ||
9International Journal of PharmaceuticsElsevier BV · Netherlands | 1.81Q1 | 4.21 0.01 up from 2012 | 1,995 | 10% | $4,650 | ||
10Pharmacogenetics and GenomicsLippincott Williams & Wilkins · United Kingdom | 1.80Q1 | 3.69 0.27 down from 2012 | 315 | 48% | — | ||
11Expert Opinion on Drug Metabolism & ToxicologyTaylor & Francis · United Kingdom | 1.72Q1 | 3.44 0.23 down from 2012 | 372 | 13% | — | ||
12Drug SafetyAdis, Springer Healthcare · New Zealand | 1.59Q1 | 2.67 1.26 down from 2012 | 360 | 23% | $4,990 | ||
13Journal of Analytical ToxicologyOxford University Press · United Kingdom | 1.56Q1 | 3.16 0.06 up from 2012 | 286 | 27% | $4,823 | ||
14Expert Opinion on Drug SafetyTaylor & Francis · United Kingdom | 1.55Q1 | 3.61 0.43 up from 2012 | 254 | 14% | — | ||
15European Journal of Pharmaceutical SciencesOAElsevier BV · Netherlands | 1.50Q1 | 3.07 0.01 up from 2012 | 739 | 14% | $3,070 | ||
16PharmacogenomicsFuture Medicine · United Kingdom | 1.42Q1 | 2.93 0.67 down from 2012 | 557 | 16% | — | ||
17Drug Metabolism and PharmacokineticsElsevier BV · Japan | 1.36Q2 | 2.92 0.61 up from 2012 | 265 | 11% | $3,580 | ||
18Clinical and Translational ScienceOAWiley · United Kingdom | 1.34Q2 | 2.53 0.04 up from 2012 | 213 | 95% | $3,630 | ||
19Drug Testing and AnalysisWiley · United States | 1.32Q2 | 2.89 0.02 down from 2012 | 418 | 9% | $4,440 | ||
20Biopharmaceutics & Drug DispositionWiley · United Kingdom | 1.27Q2 | 2.94 0.52 up from 2012 | 152 | 15% | $3,800 | ||
21Forensic ToxicologySpringer Science+Business Media · Japan | 1.22Q2 | 4.55 0.01 down from 2012 | 87 | 8% | $2,990 | ||
22AAPS PharmSciTechSpringer Science+Business Media · United States | 1.21Q2 | 2.16 0.15 down from 2012 | 548 | 100% | $4,190 | ||
23Journal of Pharmaceutical InnovationSpringer Science+Business Media · United Kingdom | 1.14Q2 | 1.52 0.16 down from 2012 | 65 | 0% | $3,990 | ||
24Drug DeliveryOATaylor & Francis · United Kingdom | 1.11Q2 | 2.51 0.06 up from 2012 | 173 | 99% | $2,864 | ||
25Current Drug DeliveryBentham Science Publishers · Netherlands | 1.11Q2 | 2.09 0.56 down from 2012 | 177 | 2% | — | ||
26XenobioticaTaylor & Francis · United Kingdom | 1.08Q2 | 2.23 0.11 down from 2012 | 363 | 14% | — | ||
27Drug metabolism and drug interactionsDe Gruyter · Germany | 0.96Q2 | 1.67 0.47 up from 2012 | 61 | 14% | — | ||
28Journal of MicroencapsulationTaylor & Francis · United Kingdom | 0.96Q2 | 2.12 0.12 up from 2012 | 274 | 6% | — | ||
29Therapeutic DeliveryFuture Science Ltd · United Kingdom | 0.95Q2 | 2.21 1.00 up from 2012 | 353 | 21% | — | ||
30Journal of Fluorine ChemistryElsevier BV · Netherlands | 0.93Q2 | 2.00 0.21 up from 2012 | 626 | 6% | $3,660 | ||
31Assay and Drug Development TechnologiesMary Ann Liebert, Inc. · United States | 0.80Q2 | 2.04 0.28 up from 2012 | 191 | 41% | — | ||
32European Journal of Drug Metabolism and PharmacokineticsAdis, Springer Healthcare · France | 0.75Q3 | 1.66 0.61 up from 2012 | 111 | 6% | $2,690 | ||
33Recent Patents on Drug Delivery & FormulationBentham Science Publishers · Netherlands | 0.75Q3 | 1.42 1.22 down from 2012 | 66 | 4% | — | ||
34Drug Delivery and Translational ResearchSpringer Science+Business Media · United States | 0.73Q3 | 1.49 0.59 down from 2012 | 120 | 34% | $4,690 | ||
35ISRN PharmaceuticsOAHindawi Publishing Corporation · Egypt | 0.72Q3 | 1.39 0.78 up from 2012 | 61 | 100% | — | ||
35Drug Development and Industrial PharmacyTaylor & Francis · United States | 0.72Q3 | 1.89 0.10 down from 2012 | 684 | 7% | — | ||
| 0.71Q3 | 1.00 0.32 down from 2012 | 64 | 0% | — | |||
38Recent Patents on NanotechnologyBentham Science Publishers · Netherlands | 0.70Q3 | 1.27 0.23 up from 2012 | 90 | 6% | — | ||
39Drug Metabolism LettersBentham Science Publishers · Netherlands | 0.68Q3 | 1.13 0.20 down from 2012 | 104 | 17% | — | ||
40Indian Journal of Pharmaceutical Education and ResearchAssociation of Pharmaceutical Teachers of India · India | 0.55Q3 | 0.62 0.42 down from 2012 | 97 | 31% | — | ||
41Pharmaceutical Development and TechnologyTaylor & Francis · United States | 0.54Q3 | 1.06 0.02 up from 2012 | 352 | 4% | — | ||
42Dissolution TechnologiesUnited States | 0.54Q3 | 1.00 0.16 up from 2012 | 100 | 90% | — | ||
43Scientia PharmaceuticaOAÖsterreichische Apotheker-Verlagsgesellschaft m. b. H. · Switzerland | 0.53Q3 | 1.93 1.20 up from 2012 | 372 | 100% | $1,207 | ||
44American Journal of Drug Discovery and DevelopmentOAUnited States | 0.41Q3 | 0.95 1.28 down from 2012 | 44 | 60% | — | ||
45Journal of Drug Delivery Science and TechnologyElsevier BV · France | 0.38Q3 | 0.79 0.60 down from 2012 | 184 | 9% | $3,810 | ||
46International Current Pharmaceutical JournalOABangladesh | 0.36Q3 | 0.70no 2012 value | 61 | 100% | — | — | |
47Journal of Drug Delivery and TherapeuticsOASociety of Pharmaceutical Tecnocrats · India | 0.33Q4 | 0.56 0.29 up from 2012 | 170 | 100% | — | ||
48Brazilian Journal of Pharmaceutical SciencesOAUniversity of São Paulo · Brazil | 0.33Q4 | 0.45 0.02 down from 2012 | 331 | 100% | — | ||
49The Open Addiction JournalOABentham Science Publishers · Netherlands | 0.29Q4 | 0.46 0.01 up from 2012 | 59 | 100% | — | ||
50Pharmacology & PharmacyOAScientific Research Publishing · United States | 0.28Q4 | 0.52 0.04 down from 2012 | 128 | 100% | — |
Subfields of Pharmacology, Toxicology and Pharmaceutics, compared.
Journals
Citations made in 2013. Corpus-wide, 76.9% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
30 additional Pharmacology, Toxicology and Pharmaceutics journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2010–2012, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2013. Publication window: 2010–2012. How these summaries are calculated
- Ranked journals
- 61
- Window papers (baseline)
- 56,245 +22.8% from indicator year 2010
- Median OJR
- 0.80 -16.1% from indicator year 2010
- Rising journals (2025)
- 4Comparison-group list (4)
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2010–2012 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 23 | 27 | 30 | 32 | 32 | 34 | 37 | 38 | 40 | 43 | 44 | 49 | 54 | 61 | 69 | 71 | 74 | 71 | 73 | 75 | 70 | 72 | 75 | 73 | 72 | 68 | |
| Window papers (baseline) | 20,428 | 21,714 | 23,158 | 25,397 | 26,889 | 29,157 | 31,606 | 34,777 | 38,146 | 41,640 | 45,814 | 49,553 | 53,613 | 56,245 | 59,173 | 59,681 | 59,061 | 56,321 | 53,536 | 51,719 | 51,606 | 54,267 | 56,608 | 57,539 | 56,944 | 58,541 | |
| Median OJR | 0.620 | 0.717 | 0.722 | 0.88 | 0.86 | 0.83 | 0.91 | 1.11 | 0.9471 | 0.97 | 0.949 | 1.03 | 0.9469 | 0.80 | 0.70 | 0.720 | 0.61 | 0.7184 | 0.74 | 0.628 | 0.77 | 0.621 | 0.67 | 0.630 | 0.625 | 0.7176 |
| Measure | Category statistic | Eligible population |
|---|---|---|
| Journal self-citation share | Median: 2.7% | 62 journals |
| Retracted papers per 1,000 | Pooled rate: 1.221 per 1,000 | 51 journals |
| Output growth | Median: -1.6% | 60 journals |
| Open access share | Median: 44.5% | 68 journals |
| Listed APC (USD) | Median including $0 listed prices: $3,605 | 32 ranked journals with a known listed price, including $0 listed prices |
| International collaboration share | Median: 22.2% | 67 journals |
| Review share | Median: 0.4% | 68 journals |
| Articles-only OJR | Median: 0.74 | 68 journals |
| Uncited share | Median: 25.2% | 68 journals |
| Citation concentration | Median: 43.7% | 68 journals |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.